EP.01A.01 Role of Diet and Exercise in Young Lung Cancer Patients with Driver Mutations (NCT04640259)

EP.01A.02 Risk Factors and Nomogram Construction of Early Death in Patients with Stage IV Lung Squamous Cell Carcinoma: A SEER-Based Study

EP.01A.04 Predictive Value of a Prognostic Model Based on Clinicopathologic Features in Lung Adenocarcinoma

EP.01A.05 Analysis of Diagnostic Delay and Its Impact on Survival in Lung Cancer Cases. Results from the Spanish Thoracic Tumor Registry

EP.01A.06 Characteristics of Non-Small Cell Lung Cancer with High Serum CEA Levels.

EP.01B.01 Geospatial Characterization of DNA Damage Repair (DDR) Mutations in Lung Cancer Patients in an Underserved Urban Population

EP.01C.01 Evolution of Lung Cancer Mortality Rates in Brazil (1996-2022).

EP.01D.01 Exploring the Association Between Connective Tissue Diseases and Lung Cancer: Analysis of the Mediating Role of Immune and Inflammatory Markers

EP.01D.02 Heterogeneous Germline Variants Detected in EGFR-Mutant Familial Lung Cancer Patients and Family Members

EP.01D.03 Analysis of Lung Cancer Risk in Never Smokers with a Family History of Lung Cancer: A Cohort Study

EP.01D.04 Impacts of Household Tobacco Smoke on Life-Long Non-Smoking Adults: An Internet-Based Population Survey in India.

EP.01E.01 Understanding the Choices of Those who Smoke Post-cancer Diagnosis

EP.02A.01 Gender-Specific Onset Age Distribution Among Different Driver Mutations in Lung Cancer

EP.02A.02 The Stroma Cell Function in the Border Region Between Lung Cancer and Normal Lung

EP.02B.01 PIK3C2A Potentiates Angiogenesis of Non-Small Cell Lung Cancer by Regulating ADRB2/VEGFA Signaling Pathway

EP.02B.02 The Functional Roles of Intergenic ALK Fusions in NSCLC

EP.02B.03 MALAT1 And NEAT1 Contribute to Adaptive Mutability in the Transition from Drug Tolerance to Drug Resistance in Lung Cancer

EP.02B.05 XBP1s-Related Super-Enhancers Suppresses Cuproptosis via Temporally Transcription Regulation in Lung Adenocarcinoma

EP.02B.06 Analysis on the Correlation Between RUNX3 Mislocalization and Epigenetic Parameters in Non-Small Cell Lung Cancer

EP.02B.07 HFE as a Novel Gene Associated with Primary Lung Cancer Risk:A Mendelian Randomization and Bioinformatics Study

EP.02B.08 Interrogating Sexual Dimorphism in Lung Cell Biology and Tumourigenesis for Cancer Treatment and Prevention in Never & Smokers

EP.02C.01 Investigating the Role of VISTA Immune Checkpoint in Human and Murine Mesothelioma Cell Lines

EP.02C.02 Stearic Acid but Not Palmitic Acid Induces Immunomodulatory Changes that Initiate Pro-Neoplastic Processes in Lung Epithelium

EP.02D.01 Macrophage Migration Inhibitory Factor Promotes Invasion and Epithelial to Mesenchymal Transition in Lung Adenocarcinoma

EP.02E.01 Development of Patient-Derived and Xenograft-Derived Organoids for Lung Adenocarcinoma Study

EP.02F.01 Berberine and Osimertinib Inhibit Progression of EGFR-TKI Primary and Acquired Resistant NSCLC Cells by a Multimodal Intervention

EP.02F.02 Individual and Combined Effects of Annonacin and 2-Deoxy-D-Glucose on Non-Small Cell Lung Cancer Cells

EP.02F.03 Elucidating the Role of XRCC6BP1 In Mitochondrial Bioenergetics and Metabolism in Non-Small Cell Lung Cancer

EP.02F.04 Development and Validation of an ADRB2-based Prognostic Model for Non-Small Cell Lung Cancer

EP.02F.05 Lysosomal Calciumrelease via TRPML3 Enhances Drug Sensitivity of Gefitinib-resistance NSCLS Cells

EP.02F.06 Suppression of Chemotherapy Induced Antiviral Signaling by YAP/TAZ in Lung Cancer

EP.02F.07 Targeting NRAS Increases Lung Adenocarcinoma Sensitivity to Paclitaxel Chemotherapy

EP.02G.01 Differentiation and Metabolic Phenotypes of Lung Squamous Cell Carcinoma Organoids are Modified by the Tumor Microenvironments

EP.03A.01 Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, Statistics and Simulation of Alive Supersystems.

EP.03B.01 The Genomic Scarring Score as a Biomarker for the Use of PARP Inhibitors in Early-Stage Non-Small Cell Lung Cancer

EP.03B.02 Association of Pre-Existing Conditions with Major Driver Mutations and Immune Contextures in Non-Small Cell Lung Cancer

EP.03B.03 Whole Genome Analysis in Resected Adenocarcinoma and Squamous Cell Carcinoma of the Lungs

EP.03B.04 Clinicopathological Features of Lung Cancers with RICTOR Gene Amplification

EP.03B.05 Construction and Validation of a Prognostic Model Using Loratadine-Related Genes in NSCLC Patient with Tumor Microenvironment.

EP.03B.06 EGFR Mutation Prevalence in Non-Lung Cancer Patients

EP.03C.01 The Impact of Systemic Inflammatory Markers on EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

EP.03C.02 The Potential of Fluoropyrimidine to be an Immunologically Optimal Partner of Immunotherapy for Thoracic Malignancies

EP.03C.03 Development of a Novel Immunotherapy for ICI Resistant KRAS-Mutantlung Cancer

EP.03D.01 Mechanistic Study of 5-Hydroxytryptamine-Mediated Promotion of Non-Small Cell Lung Cancer Metastasis by Regulation of RPL24

EP.03D.02 HNRNPC-Regulated PA2G4 Promotes Proliferation and Metastasis of LUAD Cells

EP.03E.01 Patient-Derived Organoids Can Predict Response to Chemotherapy and Targeted Thrapy in Lung Cancer Patients

EP.03E.02 Elucidation of Trastuzumab-Deruxtecan Resistance Mechanisms using in Vivo Xenograft Model Reflecting Pharmacokinetics

EP.03F.01 Modeling the Relationship of Clinical Safety Profile of EGFR Inhibitors with Wild-Type EGFR Inhibition in Cellular Model

EP.03F.02 Exploration of Acquired Resistance Mechanisms to the 4th-Generation EGFR-TKI in EGFR-Mutated Lung Cancer - An in Vitro Study

EP.03F.03 Orally Bioavailable Cyclin A/B Rxl Macrocycle has Antitumor Effect in SCLC & NSCLC Cell Line Derived (CDX) & Patient Derived Xenograft (PDX) Models

EP.03F.04 Treatment of Non-Small Cell Lung Carcinoma (NSCLC) Cells with Tumor Treating Fields (TTFields) And DNA-Dependent Protein Kinase (PK) Inhibitors

EP.03F.05 A Dose-Effect Relationship of a Novel Bronchoscopy Guided Endobronchial Radiofrequency Ablation for Peripheral Lung Tumors

EP.03G.01 Comparison of Tumor Immune Microenvironments Between Primary and Metastatic Sites in Non-Small Cell Lung Cancer

EP.03G.02 Molecular and Immune Landscape of Invasive Mucinous Adenocarcinoma (IMA) Of the Lung and Its Survival Outcome

EP.03G.03 Tumor Treating Fields (TTFields) Induce Pro-Inflammatory Phenotype Skewing of Macrophages

EP.03G.04 High SLFN11 Expression Predicts Response but is not Required to Confer Sensitivity to Lurbinectedin

EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation

EP.04A.03 Quality Implementation of Lung Cancer Screening using the QUILSTM System: Baseline Data from Ten Programs in Kentucky

EP.04A.04 Real-World Data of LDCT Lung Cancer Screening Implementation in a Public Healthcare System: Quebec Three 3-Year Experience

EP.04A.05 Lung Cancer Screening Outcomes in Aotearoa New Zealand

EP.04A.07 A Framework and Toolkit to Support the Implementation of LDCT Screening with a Focus on Inclusion of Underserved Communities

EP.04A.08 Leveraging the Quebec Lung Cancer Screening Program to Create a Collaborative Biobanking Project for Research Purposes

EP.04A.09 The Impetus, Formation and Initial Strategic Aims of the UCLCC Screening and Prevention Task Force

EP.04A.10 Creating Safe Connections: Usability Testing of an Intervention Co-designed to Increase Equitable Access to Lung Cancer Screening

EP.04A.11 Patients Reported Outcomes in Short- And Long-Term Lung Cancer Survivors Who Were Diagnosed via Chest Low-Dose CT Screening

EP.04A.12 Exploring Rural Appalachian Community Perceptions and Practices on Health and Lung Cancer to Inform Screening Interventions

EP.04A.14 Community Outreach for Lung Cancer Awareness: Utilizing the 'Cancer Challenge' to Educate the Public

EP.04A.15 Recruitment Strategies in a Lung Cancer Screening Program for Asian Women with No Smoking History

EP.04A.16 Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study

EP.04B.01 Evidence Based Communication on Lung Cancer Screening to Political Decision Makers

EP.04B.02 Identification of Circulating MicroRNAs Associated with Lung Cancer Diagnosis and Progression

EP.04B.03 The Diagnostic Efficacy of Seven Lung Cancer Autoantibodies in Early Detection of Pulmonary Ground-Glass Nodules

EP.04B.05 Discordance Between Nodule and Lung Cancer Location in Early Lung Cancer Detection Cohorts.

EP.04B.06 High-Resolution CT with 1024-Matrix for AI-Assisted Diagnosis System in the Evaluation of Pulmonary Nodules

EP.04C.01 The Value of Ultrahigh Frequency Ultrasound in Localizing Small Pulmonary Ground Glass Opacity Intraoperatively: A Prospective Study

EP.04C.02 Estimation of Numbers of Healthcare Providers Eligible for National Lung Cancer Screening in South Korea

EP.04C.04 Extended Inclusion Criteria for Lung Cancer Screening to Tabacco Related Diseases: Comparison of Preliminary Results in Two Prospective Cohorts

EP.04C.05 Projected Impact of the Age of Initiation for Lung Cancer Screening on Health Outcomes and Healthcare Resources in Canada

EP.04C.06 Investigation on the Incidence and Risk Factors of Lung Cancer Among Chinese Hospital Employees

EP.04C.08 The Potential of Chest X-Ray Artificial Intelligence Detecting Missed Lung Cancer Diagnosis in a Community Based Cancer in Thailand

EP.04C.09 Liquid Biopsy Assay to Detect Low Levels of ctDNA in Early-Stage Lung Cancer Samples

EP.04D.01 Claims-Based Yield Metric for Lung Cancer Screening

EP.04D.02 An Innovative Evidence-Based Laboratory Medicine (EBLM) Test to Help Doctors in the Assessment of Lung Cancer

EP.04D.03 Shifting Stages: Implications of a Global Pandemic on Cancer Care and A Multipronged Approach to Early Diagnosis for Non-Small Cell Lung Cancer

EP.04D.04 COVID-19 and Vaccines: A Decade of Insight from China Onpulmonary Nodules Detection and Progression

EP.04D.05 Coronary Atherosclerosis as an Incidental Finding within the Lung Cancer Screening

EP.04D.06 Observation of Peripheral Airways Using Ultra-Thin Fiberscope

EP.04E.01 Use of Routine Brain Imaging Surveillance after Definitive Treatment for Early-Stage Non-Small Cell Lung Cancer

EP.04E.02 Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis

EP.04E.03 Enzymomics of Bodily Fluids Captures CD38-Orchestrated Immunometabolic Disorder for Early Detection of Immunotherapy Toxicity

EP.04E.05 Prevalence and Characterization of MET Overexpression in Chinese NSCLC Patients: A Retrospective Real-World Analysis

EP.04E.06 The Prediction of Spread Through Air Spaces with Preoperative 18F-FDG PET/CT in Clinical Stage I Lung Cancer

EP.04E.07 Lung Cancer Patient Reported Experiences with Biomarker Testing

EP.04E.08 Rapid in House Next Generation Sequencing and Impact on Treatment Decisions and Initiation in Advanced NSCLC

EP.04F.01 Challenges in Recruiting for a Randomized Controlled Intervention to Increase Lung Cancer Screening

EP.05A.01 Efficacy and Safety of Midazolam with Fentanyl for Sedation During EBUS-TBNA: A Randomized, Double-Blind, Phase III Study

EP.05A.02 Timing of PET-CT has no Significant Impact on Staging EBUS Results in Mediastinal Staging and Diagnosis of Lung Cancer

EP.05A.03 The Accuracy of EBUS, EUS, EBUS Plus EUS, and Mediastinoscopy for Mediastinal Staging in NSCLC - A Systematic Review and Meta-Analysis

EP.05A.04 Risk Factors for the Development of Pulmonary Infection after Bronchoscopy in Patients with Lung Cancer - A Centre in Greece

EP.05A.05 Brazilian Single-Center Experience in the Staging of Thoracic Neoplasms Using Endosonographic Methods (EUS/EBUS)

EP.05A.06 Timing of Thoracentesis in Hospitalized Patients with Malignant Pleural Effusion: A Study of the US National Inpatient Sample

EP.05A.07 Feasibility and Safety of Nasal Access for EBUS-TBNA in the Korean Population: A Single Center Experiences

EP.05A.08 The Accuracy of Bronchoscopy and Transthoracic Needle Biopsy for Diagnosing Lung Cancer - A Systematic Review

EP.05A.09 The Accuracy of CT, 18FDG-PET/CT, and Mediastinoscopy for Staging in NSCLC - A Systematic Review and Meta-Analysis

EP.05B.01 Characterization of Patients with Primary Lung Cancer who Attended a Pulmonology Clinic in Bogotá, Colombia

EP.05B.02 Mucinous Adenocarcinoma of the Lung in a Brazilian Population: Clinical, Pathological, Molecular Features and Outcomes

EP.05B.03 Evaluating the Risk of Pneumonitis from G-CSF in Thoracic Cancer Patients with Pre-Existing ILD

EP.05B.05 Integrative Prediction Model for Radiation Pneumonitis: Genetic and Clinical-Pathological Factors Utilizing Machine Learning

EP.06B.01 The Actual Status of Biomarker Testing and Prognosis in Postoperative Recurrent NSCLC: Subgroup Analyses of WJOG15421L (REVEAL)

EP.06B.03 Performance of a Prognostic OTP, CD44, Ki-67 Biomarker Panel for Relapse in Paired Biopsies and Resections of Pulmonary Carcinoids

EP.06B.04 Aging Alteration of Biomarkers and Its Prognostic Role in Elderly Lung Cancer Patients Treated with Adjuvant S-1 Chemotherapy

EP.06B.05 Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes

EP.06B.06 A Meta-Analysis of Advanced Lung Index (ALI) in Advanced Lung Cancer Patients

EP.06B.07 CARE: Developing a Clinical Composite Score for mNSCLC and Co-Design Solutions to Bridge the Metropolitan vs Regional Gap

EP.06B.08 Biomarker-Guided Treatment Selection in NSCLC: A Quality Improvement Initiative to Strengthen Multidisciplinary Care

EP.06B.09 The Role of Cytokines in Predicting the Efficacy of Immunotherapy in Advanced NSCLC Patient

EP.06B.10 Clinical Feasibility of Multiplex Digital PCR for Major Mutation Detection in NSCLC Patients: The Droplex NSCLC Panel Test

EP.06B.11 Construction of a Prognostic Model for Lung Adenocarcinoma Based on Disulfidptosis-related LncRNAs

EP.06B.13 Prognostic Impact of Serum CA125 Level in Patients with cN0 Non-Small Cell Lung Cancer

EP.06B.14 Differential Expression in Potential Therapeutic Target Protein by Treatment in Small Cell Lung Cancer with and without Transformation

EP.06B.15 Targetable Genetic Alterations Associated with Non-Small Cell Lung Cancer Mortality

EP.06B.16 Latin-American Non-Small Cell Lung Cancer Patient's Tumors Harbor Many Novels Potentially Actionable/driver Mutations.

EP.06B.17 Detection of EGFR Mutations T790M and L858R for Therapeutic Guidance of NSCLC

EP.06B.18 Biomarker Landscape of Antibody-Drug Conjugates and Bispecific Antibodies in Clinical Trials for Lung Cancer

EP.06B.19 WNT/ß-Catenin Signalling Pathway in Non-Small Cell Lung Cancer: Study of Immuno-expression GSK-3ß, ß-Catenin, And CD44.

EP.06B.20 Prognostic Impact of Nectin-like Molecule-5 (CD155) Expression in Non-Small Cell Lung Cancer

EP.06C.01 KRAS Q61H Mutation Defines a Distinct Clinicopathological Entity of Lung Adenocarcinomas in East Asian Patients

EP.06C.02 Clinical Features and Survival Outcome of Lung Invasive Mucinous Adenocarcinoma: A Real-World Analysis of 387,197 Patients

EP.06C.03 Clinicopathological Analysis of Each EGFR Status in Surgically Resected Lung Adenocarcinoma: A Real-World Study (CReGYT-01 EGFR)

EP.06C.04 Impact of TP53/EGFR Mutations in Advanced-Stage NSCLC: LATAM Population

EP.06C.05 Impact of TP53 Mutation in Advanced NSCLC in LATAM

EP.06C.06 Outcome and Clinical Profile of Common and Uncommon EGFR Mutations in NSCLC: Retrospective Analysis from an Argentinean Cancer Center

EP.06C.07 Impact of a Diagnostic Bronchoscopy Service with Embedded Reflex Molecular Testing within an Oncology Centre in Patients with Lung Cancer.

EP.06D.01 Prognostic Evaluation by Using ctDNA in Patients with EGFR Mutated Resectable Lung Cancer

EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

EP.06D.03 Concurrent Liquid and Tissue Biopsy from Same Laboratory Increases On-Label Alteration Detection with Faster Turnaround Time

EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer

EP.06D.05 The Prognostic Role of the Dynamic Changes in the Plasma ctDNA Levels in Advanced NSCLC after IO Initiation: A Meta-Analysis

EP.06E.01 Preexisting CD153+CD4+ T Cells Cause Lung Specific Toxicity via Type 3 Immunity without Kidnapping Efficacy in Immunotherapy

EP.06E.03 Body Composition and Inflammation Index-Based Nomograms to Assess the Outcomes of Patients with NSCLC Receiving Chemoimmunotherapy

EP.06E.05 Is Diffusion-Weighted Imaging Able to Indicate Pathological Response in NSCLC after Neo-Adjuvant Immuno-Chemotherapy?

EP.06E.06 Elucidating the Interplay Between Oncogenic Fusions and the Tumor Immune Microenvironment in Lung Adenocarcinoma

EP.06E.07 Geospatial and Molecular Characterization of Tumor Immune Cell Infiltration in NSCLC

EP.06E.08 Clinical Significance of JPH4 and Correlation with the Immune Microenvironment of Lung Adenocarcinoma

EP.06E.09 Spatial Multiomics Analysis Reveals AT2 Cells Inhibit B Cells of TLS in Pre-invasive Lung Adenocarcinoma after Neoadjuvant Immunotherapy

EP.06F.01 Survival Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination

EP.06F.02 Enhancing Clinical Utility: Oncomine Dx Target Test Augments Biomarker Detection in Advanced Non-Small-Cell Lung Cancer

EP.06F.03 Analysis of Copy Number Variations of MET, EGFR and ERBB2 Genes in a Lung Cancer Patient Series: Comparison of FISH with NGS

EP.06F.04 The Characteristics of Plasma Sample NGS Analysis in the Detection of Lung Cancer Driver Genes

EP.06F.05 External Quality Assessment Results of Third-party NGS Laboratories in China for the Detection of Rare Mutations in Lung Cancer

EP.06F.06 Concurrent DNA and RNA NGS Testing to Characterize Rare Fusions in Advanced NSCLC Patients

EP.06F.07 Comparison Between EGFR PCR Alone and NGS with Gene Fusion PCR for Detecting Oncogenic Driver Alteration in Thai NSCLC Patients

EP.06F.08 Cancer Evolution Analysis for Lung Carcinomas with Multiple Driver Mutations

EP.06F.09 Epidemiological Profile of Patients with Non-Small Cell Lung Cancer Treated at Oncologia D' or Bahia from January 2018 to December 2022.

EP.06G.01 Prognostic Significance of Purinergic Receptor- and Ectonucleotidase- Expression in NSCLC Tumor Cells and Stroma

EP.06G.02 Profiling the Metastatic Potential of Non-Small Cell Lung Cancer Patients Based on TP53 Classification

EP.06G.03 Newly WHO Reporting System for Lung Cytopathology: Reproducibility Test of the Diagnosis

EP.06G.04 Clinicopathological Differences between EGFR Mutated and EGFR Wild-Type Lung Adenocarcinoma with Papillary Predominant Pattern

EP.06G.05 Molecular Characteristics of Pulmonary Lymphoepithelioma-Like Carcinoma in the Chinese Population

EP.06G.08 Clinicopathologic and Molecular Features of SWI/SNF-Deficient Thoracic Tumors

EP.06G.09 Harnessing Real-World Data for Translational Research in Lung Cancer: MD Anderson Thoracic GEMINI Program

EP.06G.10 Comprehensive Analysis of the Clinicopathological Features, Targetable Profle, and Prognosis of Mucinous Adenocarcinoma of the Lung

EP.06G.11 Effects of Gut Microbiota and Metabolites on Peritoneal Metastasis of Non-Small Cell Lung Cancer

EP.06G.12 The Fibrosis Around the Pulmonary Artery Is Associated with Difficulty in Dissection During Surgery after Systemic Therapy

EP.06G.13 TP53 Somatic Mutation and its Association with Clinicopathological Parameters and Long-Term Clinical Outcome in Non-Squamous NSCLC Patients

EP.06G.14 Discovery of Immune-Related Long Noncoding RNA Signatures in Lung Adenocarcinoma

EP.06G.15 Rapid Immunohistochemistry of Microsatellite Instability Using Non-Contact Alternating Current Electric Field Mixing

EP.06G.16 Pleural Fluid EGFR Mutation Testing in 10 Patients with Advanced Lung Adenocarcinoma with Pleural Effusion

EP.06G.17 A Clinical Conundrum: Lung Cancer in the Breast

EP.06G.19 Characterization of Metabolomic Landscape in Underrepresented Patients with Lung Cancer

EP.06G.20 Advanced Squamous Cell Lung Carcinoma in Never Smokers: A Different Entity? Analysis from the Thoracic Tumor Registry in Spain (RTT)

EP.07A.01 Association Between Surgical Approach < Surgical Outcome in Lung Cancer Patients Undergoing Segmentectomy

EP.07A.02 Staple Formation by Endostapler and Bronchial Wall Thickness in Pulmonary Lobectomy: Prospective Observational Study

EP.07A.03 Influence of Preoperative Percutaneous Transthoracic Lung Biopsy on Recurrence and Mortality after Surgery for Lung Cancer

EP.07A.04 Risk Factor Analysis and Predictive Model for Air Leakage after Thoracoscopic Lung Wedge Resection

EP.07A.05 Evolution of Use of Sublobar Resection in a US Population-Based Cohort Before and after Two Randomized Controlled Trials

EP.07A.06 Usefullness and Appropriate Indication of Intraoperative CT-Guided Marking Using O-Arm Based on Cancellation Rate

EP.07A.07 Comparison of Inpatient Opioid Use and Pain Control Following Thoracoscopic Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer

EP.07A.08 Modified Periareolar Incision for Uniportal Segmentectomy

EP.07A.09 A New Method to Detect Air Leaks in Video-assisted Thoracoscopic Surgery Using Indocyanine Green Inhalation Under Near-infrared Fluorescence

EP.07A.10 Concordance Between Lymph Node Station Examination Reported on a Checklist and the Final Pathology Report after Curative Lung Cancer Resection

EP.07A.11 AI Models for Intraoperative Diagnosis Based on Surgical Resection Images in Stage IA LUAD: A Prospective, Multicentric Study

EP.07A.12 Association Between Preoperative Diaphragm Thickness and Postoperative Complications in Elderly Patients with Lung Cancer

EP.07A.13 The Comparison of Early Surgical Outcomes and Lung Function Change after Complex Basal Segmentectomy and Lower Lobectomy

EP.07A.14 The Postoperative Chest Tube Drainage Strategy of "Lesstube" Can Reduce Patient Pain and Shorten Hospital Stay

EP.07A.15 Prognosis after Surgical Treatment of Lung Cancer with Multifocal Ground-Glass Nodules: The Effect of Nodule Characteristics

EP.07A.16 The Prognostic Disparities Between the T3 Descriptors in Surgically Resected Primary Lung Cancer

EP.07A.17 One-Stage Versus Two-Stage Thoracoscopic Surgery for Synchronous Bilateral Pulmonary Nodules: A Propensity Score-Matched Analysis

EP.07A.18 Do Excessive Delays Affect Pathologic Upstaging for Early Lung Cancer?

EP.07A.19 Impact of Preoperative Pulmonary Function on Survival Following Lobectomy for Stage I and II Lung Cancer

EP.07A.20 Intraoperative Near-infrared Fluorescence Visualization of the Pulmonary Bronchus with Indocyanine Green Inhalation

EP.07A.21 Tubeless Strategy after Thoracoscopic Pulmonary Wedge Resection: A Better Choice for Specific Patients

EP.07A.22 The Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma

EP.07A.23 Initial Experience of Robotic Assisted Pulmonary Resection Using a Novel Surgical Robot with Haptic Feedback Function

EP.07A.24 European Experience of Early-Stage NSCLC Patients with Any Prior Cancer History Following Lobectomy or Segmentectomy

EP.07A.25 Portable Cone Beam CT for Intraoperative Marking of Small Pulmonary Nodules; Anywhere, Anytime!

EP.07A.26 A Novel Four-Hook Puncture Needle for Accurate Localization of Small Pulmonary Nodules in VATS: A Single-Center Retrospective Study

EP.07A.27 Change in Quality of Life for Robotic-Assisted Surgery and Video-Assisted Thoracoscopic Surgery in Stage IA Non-Small Cell Lung Cancer Patients

EP.07B.02 Comparative Outcomes of Surgery and SBRT for Stage I Lung Cancer in Koreans: A Propensity Matched Multidisciplinary Cohort Study

EP.07B.03 Analysis of 30- And 90-day Mortality after Lung SBRT as an Indicator for Its Appropriateness

EP.07B.04 Two-Stage Bilateral Video-Assisted Thoracic Surgery Combined with Gefitinib for Bilateral Primary Lung Cancer: A Case Report

EP.07B.05 Comparison of Image-Guided Thermal Ablation or Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer

EP.07B.06 Transplant Patients with Medically Inoperable Early-Stage Lung Cancer Have Worse Outcomes When Treated with SBRT

EP.07B.07 The Impact of Radiation Therapy on Lung Cancer Patients with Interstitial Lung Disease

EP.07B.08 The Treatment Outcome of SBRT and Sublobar Resection for Vulnerable Elderly Patients with Stage IA Non-Small Cell Lung Cancer

EP.07B.09 Lymph Node Evaluation for Stage Cia Non-Small Cell Lung Cancer: Findings from a Single Institution

EP.07C.01 Neoadjuvantimmunochemotherapy Versus Chemotherapy for Elderly Patients with IB-IIIB Non-Small-Cell Lung Cancerin Real-World Practice

EP.07C.02 Perioperative Cadonilimab and Chemotherapy in Stage II-IIIA Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study

EP.07C.03 Oncological Outcomes after Lobe-Specific Mediastinal Lymph Node Dissection in Thoracoscopic Right Upper Lobectomy for Clinical N0 NSCLC

EP.07C.04 Adjuvant Aumolertinib in Resected Stage I EGFR-Mutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions

EP.07C.05 Efficacy and Safety of Aumolertinib in Stage IB-IIIA NSCLC after R0 Resection and the Correlation Between Efficacy and Postoperative MRD Status

EP.07C.08 Surgical Factors and Adjuvant Therapy Use after Neoadjuvant Therapy for Patients with Resected Stage II-IIIB(N2) NSCLC

EP.07C.09 Neoadjuvant Chemoimmunotherapy (CIT) In Resectable Non-Small Cell Lung Cancer (NSCLC): Real-World Treatment Patterns and Surgical Outcomes

EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer

EP.07C.11 Adjuvant Immunotherapy for Patients with Resectable NSCLC after Pathologic Complete Response

EP.07C.13 Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors

EP.07C.14 Clinical Outcomes of Neoadjuvant Immunotherapy in Stage I-II Non-Small Cell Lung Cancer: A Real-World Study and Meta-Analysis

EP.07C.15 Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study

EP.07C.16 Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy

EP.07C.17 A Nomogram Prediction Model for Assessing the Risk of Recurrence in NSCLC Patients Underwent Neoadjuvant Immunotherapy: A Retrospective Study

EP.07D.01 Regional Longitudinal Evaluation of Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer (ELEVATE)

EP.07D.02 Comprehensive Treatment Availability is Associated with Improved Outcomes Among Veterans with Early-Stage Lung Cancer Treated at VA Hospitals

EP.07D.03 A Quality Improvement Initiative to Address Biomarker Testing and Quality of Care Delivery for Early-Stage NSCLC at 3 Cancer Centers in the US

EP.07D.04 Outcomes with Evolving Patterns of Neoadjuvant Therapy: A Population-Based Analysis

EP.07D.05 Molecular Testing Care Gap Analysis of EGFR Mutation for Early-Stage NSCLC Patients in Community Practices

EP.07D.07 Assessing the Adoption of Combined Immunotherapy and Chemotherapy in Eligible Patients with Non-Small Cell Lung Cancer

EP.07D.09 A Global Study to Evaluate Access and Dynamics of Multidisciplinary Teams Care and Biomarker Testing in Early-Stage NSCLC

EP.07D.10 Deciphering Destiny: Is Curation of NSCLC Limited to Stage IA?

EP.07E.01 Intrinsic Impacts of the Expression of PD-L1 On Postoperative Recurrence in EGFR-Mutated Lung Adenocarcinoma

EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma

EP.07E.04 Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs

EP.07E.05 Prevalence of EGFR Mutations (EGFRm)in Patients with Early-Stage NSCLC - Results from EARLY-EGFR Thailand Study

EP.07E.06 Long-Term Outcomes of Resected EGFR-Mutated Lung Adenocarcinoma - A Single Centre UK Experience

EP.07E.07 Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations

EP.07F.02 Preoperative Tumor-Derived Exosomes Enhanced the Accuracy of Identifying Spread Through Air Spaces from Intraoperative Frozen Sections

EP.07F.03 The Mutation Landscape & Clinical Features of Taiwanese NSCLC Detected by Low-Dose CT

EP.07F.04 Differences in High-Order, Three-Dimensional Chromatin Structure Between Tumor and Adjacent Normal Tissues in Lung Adenocarcinoma

EP.07F.05 The Neutrophil/Lymphocyte Ratio Predict Lymph Node Metastasis in Patients with Clinical Stage T2 Non-Small Cell Lung Cancer.

EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold

EP.07F.08 Clinical Significance of Endothelial Programmed Cell Death Ligand 1 Expression in Patients with Non-Small Cell Lung Cancer

EP.07G.01 Computed Tomography Features of Pathological Stage IA Lung Adenocarcinoma Showing Spread Through Air Spaces.

EP.07G.02 Nomogram Model for Predicting Risk of Spread Through Air Space in Stage IA Sub-centimeter Non-Small Cell Lung Cancer

EP.07G.04 Clinical Implications of Spread Through Air Spread as Prognostic and Predictive Factors for Patients with Stage IA-B Non-Small Cell Lung Cancer

EP.07G.05 Maximum Standardized Uptake Value and Cell-Free DNA to Predict Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer

EP.07G.06 Utilization of Tissue-Free Minimal Residual Disease MRD Testing in Early-Stage Lung Cancer Patients from Asia and the Middle East

EP.07G.07 Risk and Outcomes of Secondary Malignancy Among Non-Small Cell Lung Cancer Survivors Following Definitive Treatment

EP.07H.01 Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN)

EP.08A.01 Impact of Locoregional Recurrence Versus Distant Metastasis on Survival in Patients with NSCLC after Surgery: A Secondary Analysis of PORT-C RCT

EP.08A.02 Adherence to Adjuvant Immunotherapy and Target Therapy Protocols Inpatients with Resected NSCLC: A Meta Analysis

EP.08A.03 Real World Outcomes of Adjuvant Atezolizumab in NSCLC: A Single Institution Study

EP.08B.01 Heterogeneity of Peripheral Blood Cell Dynamics and Oncologic Outcomes Between LUAD and LUSC Receiving Neoadjuvant Immunochemotherapy

EP.08B.02 The Impact of C-Met Expression on the Immune Microenvironment and Survival in Locally Advanced Non-Small Cell Lung Cancer

EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.

EP.08C.02 Impact of Non-Coplanar Radiation Beam Geometry on Effective Dose to Immune Cells (EDIC) In Stage III NSCLC

EP.08C.03 To Construct Multi-Omics Modelfor Predicting Prognosis of Definitive Chemoradiotherapyin Locally Advanced Non-Small Cell Lung Cancer

EP.08C.04 Personalized ctDNAand CTC Dynamic Monitoring to Predict Response of Tislelizumab-Based Therapy in Unresectable LA-NSCLC

EP.08D.02 Adjuvant Treatment Options after Neoadjuvant Chemotherapy Combined with Immunotherapy and Surgery in Patients with Non-Small Cell Lung Cancer

EP.08D.03 Efficacy of Neoadjuvant Immunochemotherapy in the Treatment of Stage III Non-Small-Cell Lung Cancer with Cancer-driven Gene Mutations

EP.08D.04 Association of Lymph Node Metastatic Patterns and Neoadjuvant Immunochemotherapy Effectiveness in Resectable Non-Small Cell Lung Cancer

EP.08D.05 Long Term Follow-up of Two Decades Experience with Neoadyuvant Chemotherapy in Resectable Non Small Cell Lung Cancer

EP.08D.07 Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC

EP.08D.08 Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated

EP.08D.09 Efficacy and Safety of Neoadjuvant Tislelizumab Plus Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: a Pooled Analysis

EP.08D.10 Outcome after Preoperative Chemoradiotherapy for Non-Small Cell Lung Cancer with Chest Wall Invasion

EP.08D.11 Redefining Prognosis in NSCLC after Neoadjuvant Immunotherapy: The Predictive Power of Pathologic Response and Lymph Node Status

EP.08D.13 Macrophage Polarization States Predicting the Efficacy of Neoadjuvantchemoimmunotherapyin Resectable or Potentially Resectable NSCLC

EP.08D.14 Long-Term Prognosis of Patients Undergoing Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer

EP.08D.15 Radical Surgery after Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer

EP.08D.16 Neoadjuvant Chemoimmunotherapy in the Treatment of Stage III Non-Small Cell Lung Cancer: A Single-Center Initial Results.

EP.08D.17 Long-Term Survival Outcomes of Surgery after Neoadjuvant TKI for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutations

EP.08E.01 Comparison of CT Findings Between Staple Line Granuloma and Recurrent Tumor after Sub-Lobar Resection for Lung Cancer and Pulmonary Metastasis.

EP.08E.02 Long Term Impact of IASLC Uncertain Resection (Run) Definition in Surgically Resected pN2 Non-Small Cell Lung Cancer

EP.08E.04 Not all pN1 Are the Same: Stations 12-14 Involvement, an Independent Prognostic Factor of Better Survival

EP.08E.05 The Presence of NSCLC Results in Diminished Ventilation in the Affected Lung

EP.08E.06 The Peripheral Bronchial Occlusion or Stenosis after Dumon Y-stenting is Prognostic Factor in Patients with Advanced Lung Cancer

EP.08E.08 Local Advanced Lung Cancer: Artificial Intelligence, Complex System Analysis, Simulation of Alive Supersysems for Optimal Management

EP.08E.09 Safety and Feasibility of Uniportal Robotic Lung Resection

EP.08F.01 Predicting Radiation Pneumonitis with Baseline Pulmonary Function Tests in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

EP.08F.02 Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors

EP.08F.03 Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study

EP.08F.04 Development of Learning-Based Predictive Models for Radiation-Induced Atrial Fibrillation in Non-Small Cell Lung Cancer

EP.08F.05 Real World Evidence of Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: AYAME Study

EP.08F.06 Concurrent Chemoradiotherapy Followed by Durvalumab for Elderly Patients

EP.08F.07 Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Patients with Stage III Non-Small Cell Lung Cancer

EP.08F.08 Safety and Efficacy of Durvalumab Consolidation Therapy after Chemoradiotherapy in NSCLC Patients Positive for Antinuclear Antibodies

EP.08F.10 Semi-Automated NSCLC Segmentation and RECIST Measurement: Bridging the Gap Between Speed and Radiologist-Level Accuracy

EP.08F.11 Development of Clinical Prediction Model Using Digital Device for ILD in the Stage III NSCLC Patients Treated with Durvalumab

EP.08F.12 Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada

EP.08F.13 Machine Learning Analysis of Cardiac Sub-Structure Dose and Overall Survival of NSCLC Pts Treated with Concurrent Definitive Chemoradiotherapy

EP.08F.14 Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective Real-World Study

EP.08F.15 A Retrospective Study of Tislelizumab Combined with Chemotherapy in Patients with Locally Advanced Lung Cancer

EP.08F.16 Re-Irradiation with Chemotherapy with/without Immunotherapy for In-Field Local Recurrence Among Lung Cancer Patients

EP.08F.18 Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database

EP.08F.19 Dosimetric Benefits in Adaptive Intensity Modulated Radiotherapy with Sib for Lung Cancer: An Indian Regional Cancer Centers' Early Experience

EP.08F.20 Stage IIIA Non-Small Cell Lung Cancer (NSCLC): Outcomes by Treatment Strategy

EP.09A.01 Oligoprogression after Local Ablative Treatment for Oligometastatic Non-Small Cell Lung Cancer

EP.09A.02 Addition of Pulsed Electric Field Ablation to SBRT for Lung Tumors: Effect on Health-related Quality of Life

EP.09A.03 Safety and Efficacyof Cranial Radiotherapy in Combination with Aumolertinibin EGFR-Mutant NSCLC Patients with Brain Metastases

EP.09A.04 Enhancing Radiotherapy Efficacy for Brain Metastases in Non-Small Cell Lung Cancer Through the Integration of G-CSF and Immunotherapy

EP.09A.05 Consolidative Thoracic Radiotherapy Induced Lymphopenia in Metastatic NSCLC Is Predicted by EDIC and Associated with Poor Clinical Outcomes

EP.09A.06 Assessment of Treatment Outcomes and Chest Wall Toxicity Following Stereotactic Body Radiotherapy for Lung Nodules Adjacent to the Pleura

EP.09A.07 Prognostic Factors for Advanced Invasive Mucinous Adenocarcinoma of the Lung with Emphasis on the Treatment Modalities

EP.09B.01 Closing the Gap: Moving Toward Equitable Care in Surgical Management of Stage IV Lung Disease

EP.09B.02 Performing Lung Resection Simultaneously with Cardiac Valve Surgery is Safe and Economical

EP.09B.04 Neoadjuvant Chemo-Immunotherapy Followed by Radical Surgery for Synchronous Oligometastatic Non-Small Cell Lung Cancer

EP.09B.05 The Role of Pulmonary Metastasectomy (PM) For Non-Primary Lung Cancer: Umbrella Review of Meta-Analyses

EP.11A.02 Pretreatment Plasma sCD14 as a Prognostic Indicator in aNSLC Patients Undergoing Immunotherapy

EP.11A.03 Anti-PD-1 Therapy Plus Denosumab in Advanced Non-Small Cell Lung Cancer with Bone Metastases: A Single-Centre, Retrospective Study in China

EP.11A.04 Patterns of Failure and Subsequent Treatment after Progression on First-Line Immunotherapy Monotherapy in Advanced NSCLC

EP.11A.05 Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience.

EP.11A.06 Somatic Gene Changes Associated with Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

EP.11A.07 Immunotherapy in Metastatic Pulmonary Lymphoepithelioma-Like Carcinoma

EP.11A.08 Real-World Comparative Effectiveness in Advanced NSCLC and High PD-L1 with 1L Immune Checkpoint Inhibitors ± Chemotherapy

EP.11A.09 Predictive Role of BMI and Inflammation Markers in Immunotherapy (ICI) For HIV Associated Lung Cancer

EP.11A.10 Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

EP.11A.11 Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study

EP.11A.12 Real-World Treatment Patterns and Clinical Outcomes Following Chemotherapy and Anti-PD-(L)1 In Non-Small Cell Lung Cancer

EP.11A.13 Efficacy and Safety of Immune-Checkpoint Inhibitors in Advanced NSCLC Patients with Rare Mutation after Developing Targeted Therapy Resistance

EP.11A.14 Impact of Immune-Related Adverse Event Severity on Overall Survival in Patients Receiving PD-1/L1 Therapy, with a Focus on Combination Regimens

EP.11A.15 NSCLC-ClustOpt: A Semi-Supervised Optimized Clustering to Stratify Patients with NSCLC on Immune Checkpoint Blockers Therapy

EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study

EP.11A.17 Efficacy and Influencing Clinical Factors of Tislelizumab Combined with Chemotherapy Plus Bone-Targeted Agents for NSCLC Bone Metastasis

EP.11A.18 LUMINATE 101-Maccabi: Real-World Study of Treatment Patterns and Clinical Outcomes in Patients with Mnsclc in an Israeli HMO

EP.11A.19 Efficacy and Outcomes of Immunotherapy-Based Treatments in EGFR-Mutant Non-Small Cell Lung Cancer

EP.11A.20 Incidence and Outcomes of Adrenal Oligoprogression in Metastatic Lung Cancer During Immunotherapy

EP.11A.21 Target Switching as an Effective Second-Line Strategy for Refractory Metastatic NSCLC

EP.11A.22 Comparing Outcomes and Adverse Events in Lung Cancer Immunotherapy: The Impact of Smoking Status

EP.11A.23 REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina

EP.11A.24 Clinical Prognostic Index for Immunochemiotherapy in Lung Cancer (CLIPI-LC)- A Prognostic Score for Advanced Non-Small-Cell Lung Cancer

EP.11A.25 Consensus on Maintenance Therapy after a First-Line Pembrolizumab-Containing Regimen in Advanced/metastatic NSCLC

EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data

EP.11A.28 Efficacy and Safety of Penpulimab-Containing Regimens for Advanced Malignant Solid Tumors That Have Failed Immunotherapy: A Real World Study.

EP.11A.29 C-Reactive Protein's Impact on Immune Adverse Events in Non Small Cell Lung Cancer Patients Undergoing Immunotherapy: Meta-Analysis

EP.11B.02 Correlation Analysis of Peripheral Blood Cell Immune Phenotype with Prognosis of Immunotherapy in Advanced Non-Small Cell Lung Cancer

EP.11B.03 Body Mass Index and Genetic Association in Durable Responders to Immunotherapy in Metastatic Non-Small Cell Lung Cancer

EP.11B.04 Differential Durable Responses in Intrathoracic Versus Overall Lesions of Non-Small Cell Lung Cancer Treated with Immunotherapy

EP.11B.05 The Differential Effect of Radiation, IL39, and the Combination on Expression of HLA Molecules

EP.11B.06 The Impact of Body Mass Index on Immune-Related Adverse Events and Outcomes in Patients with Lung Cancer: A Real-World Study

EP.11B.07 Choline Metabolism Reprogramming Mediates an Immunosuppressive Microenvironment in Non-Small Cell Lung Cancer

EP.11C.01 Treatment Options for Tumor Progression after Initial Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study

EP.11C.02 Role of Immune-Related Adverse Events (irAEs) and Albumin in Non-Small-Cell Lung Cancer (NSCLC)

EP.11C.03 Anlotinib Combined with Immune Checkpoint Inhibitor May Benifit Advanced Smarca4-Deficient Thoracic Tumor Patients in First Line

EP.11C.04 Retrospective Evaluation of Biomarkers (KRAS, TP53, STK11, KEAP1, POLE, PIK3CA, ARID1A) In Patients with NSCLC IV

EP.11D.01 A Phase II Study of Cadonilimab Plus Chemotherapy as First-Line Treatment for PD-L1-Negative Advanced Non-Small Cell Lung Cancer:LungCadX

EP.11D.02 An Investigator-Initiated Phase II Study of Combination Treatment of Nivolumab and TM5614, A PAI-1 Inhibitor for Previously Treated NSCLC

EP.11E.01 Immune-Related Myasthenia Gravis in Patients with NSCLC: A Case Series

EP.11E.03 Therapeutic Efficacy of Immunotherapy and Chemotherapy in Metastatic Nuclear Protein in Testis Carcinoma with NUTM1::NSD3 Mutation Originating from the Bronchus: A Case Report

EP.11E.04 Low-Dose Nivolumab in Advanced NSCLC; Light at the End of the Tunnel

EP.11E.05 Outpatient Treatment Strategies for Grade 3-4 Immune-Mediated Hepatitis in Patients with Lung Cancer

EP.11E.06 "Down-Stage" To Thoracic Surgery after Neoadjuvant Immunochemotherapy

EP.12A.01 Preclinical Characterization of a Potent, Selective, Brain-Penetrant Inhibitor of Osimertinib-Resistant EGFR Variants

EP.12A.02 What is the Optimal First-Line Regimen for EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US

EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer

EP.12A.05 Evaluation of the Role of VAF/cellularity as Proxy of Gene Aberration in EGFR Mutated Advanced NSCLC During Osimertinib

EP.12A.06 Diarylheptanoid 35d Overcomes EGFR TKI Resistance by Inducing EGFR Degradation in EGFR-Mutant Lung Adenocarcinoma

EP.12A.07 Restoring Expression of Tumor Suppressor PTEN by Engineered Circular RNA Enhances Osimertinib Sensitivity in Non-Small Cell Lung Cancer

EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study

EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients

EP.12A.12 Lazertinib as Second-Line or Greater Treatment is More Effective in Patients who Showed Extended Response to Prior TKI in Advanced NSCLC

EP.12A.13 CRISPR with Double Mismatch Guide RNA Enhances Detection EGFR Mutation in Circulating Cell-Free DNA of Lung Cancer Patients

EP.12A.14 Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) In Thailand

EP.12A.15 ACTN4 as a Predictive Biomarker for Osimertinib Efficacy in EGFR Mutant Non-Small Cell Lung Cancer

EP.12A.16 High-Dose Aumolertinib Combined Intrathecal Chemotherapy for the Treatment of EGFR-Mutated NSCLC with Leptomeningeal Metastasis

EP.12A.17 Impact of Osimertinib and Cranial Therapy on EGFR-Mutated Lung Cancer with Brain Metastasis: A Single-institution Retrospective Study

EP.12A.18 Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations

EP.12A.19 Race May Affect Survival in 1L Patients with Metastatic Non-Small Cell Lung Cancer (mNSLC) Onegfr-Targeted Therapy

EP.12A.20 EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma

EP.12A.21 Nimotuzumab Plus Chemotherapy in the Posterior Line Therapy of EGFR-TKIs Resistant Lung Adenocarcinoma: A Case Series Study

EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study

EP.12A.23 PD-L1 Induced Resistance to EGFR-TKIs in Lung Adenocarcinoma

EP.12A.24 Prognostic Value of Functional Subtype Classification of Co-Occurring TP53 Mutations in Patients with EGFR-Mutant NSCLC Treated with TKI

EP.12A.25 Concurrent RB1/TP53 Alterations in Targetable EGFR-Mutant Lung Adenocarcinoma Imply Aggressive Treatment

EP.12A.26 Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam

EP.12A.27 Targeting DDR Pathway Activates the TBK1-NF?B P65 Axis and Enhances the Killing Effect of CD8+ T Cells

EP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment

EP.12A.29 Characteristics of Osimertinib Non-Responders vs Responders in EGFR Mutated Lung Cancer

EP.12A.30 Landscape of EGFR Mutations and Real-World Experience of Therapeutic Interventions - A Community Oncology Study

EP.12A.31 Clinical Characteristics and Outcomes of EGFR-Positive Non-Small Cell Lung Cancer with Acquired RET Fusions

EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities

EP.12A.33 A Comparative Analysis of Outcomes in Patients with Single EGFR Muations for Concurrent Gene Alterations

EP.12A.34 Chemotherapy and/or Immunotherapy after Progression on Tyrosine Kinase Inhibitors in EGFR Mutant Non-Small Cell Lung Cancer Patients.

EP.12A.35 A Phase I Open-label Study Ofnimotuzumab with Nivolumab in Advanced Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Cancer

EP.12A.36 Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America

EP.12A.37 Erlotinib: A Beacon of Hope in EGFR TKI-Progressed Lung Cancer, A Real-World Experience from a Tertiary Care Cancer Centre in South India

EP.12A.38 Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series

EP.12A.39 MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review.

EP.12A.40 Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and Met-Amplification: A Case Series

EP.12A.42 Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor

EP.12A.43 Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients: A Case Series

EP.12A.44 Short-course Immunotherapy Prior to Targeted Therapy in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

EP.12A.45 Study of the Mutational Profile of EGFR-Mutated Lung Cancer in the Russian Population on the Example of the City of Moscow

EP.12A.47 Befotertinib (D-0316) Plus Icotinib as First-Line Therapy for Patients with EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

EP.12B.01 Weight Gain and Metabolic Changes Associated with Alectinib Use in ALK-Positive Lung Cancer

EP.12B.02 Real-World Treatment Patterns and Effectiveness in Patients with ALK+ Advanced NSCLC Treated with 1L ALK TKIs

EP.12B.03 Cognitive Impact of Lorlatinib Administration in Advanced Non Small Cell Lung Cancer with ALK and ROS1 Fusions

EP.12B.04 BMF Deficiency Leads to an Increase of Drug Tolerant Persister Cells in ALK-Positive Lung Cancer

EP.12B.05 Drivers of Treatment Choice in ALK-Positive Metastatic Non-Small Cell Lung Cancer from Patients' and Caregivers' Perspectives

EP.12B.06 Efficacy of Lorlatinib in Advanced ALK-Positive Non-Small Cell Lung Cancer Patients in Thailand: A Multicenter Study

EP.12B.07 Identification of Candidate Therapeutic Targets Using Single Cell RNA Sequencing in ALK-Positive Lung Cancers

EP.12B.08 Characterizing the Severity and Timing of Real-World ALK-Inhibitor Associated Weight Gain in Non-Small Cell Lung Cancer

EP.12B.09 Real-World Efficacy and Toxicity Comparison Between the RET Inhibitors (RETi) Pralsetinib and Selpercatinib in Patients with Stage IV NSCLC

EP.12B.10 Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)

EP.12B.11 Clinical Treatment Selected by Patient-Derived Organoid in a Patient with Stage IV Lung Adenocarcinoma with Unique ALK Alternation

EP.12B.12 Intrinsic ALK-TKI Resistance Due to Met-Coamplification in ALK+ NSCLC, Effectively Treated by Alectinib-crizotinib Combination

EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series

EP.12B.15 ALK-Fusion Positive NSCLCs: Diversity in Mutations and Co-Mutations with Therapeutic Perspective and Clinical Outcomes

EP.12B.16 Effectiveness of Alectinib in ALK Rearrangement NSCLC: Real World Data of Peru

EP.12C.01 Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer

EP.12C.02 5-Azacytidine DegradedKRAS By Recruiting E3 Ubiquitin Ligase UBE3C

EP.12C.03 Toxicities Associated with Immune Checkpoint Inhibitors Followed by KRAS G12C Inhibitors in Patients with Metastatic NSCLC

EP.12C.04 Location of Metastases and Prognosis of Patients with Metastatic KRAS-Mutant Non-Small Cell Lung Cancer

EP.12C.05 KRASG12c-Mutant NSCLC Under Targeted Therapy in China: Lessons from Eight Cases

EP.12D.01 Clinical Outcomes of Patients with HER2-Mutant NSCLC in Real-World Settings: A Systematic Literature Review

EP.12D.02 Treatment Strategies and Survival Outcomes of Advanced NSCLC with HER2 Mutation and BM: A Multicenter Retrospective Study

EP.12D.03 Characterization of HER2Alterations in 23,321 NSCLC Cases and Real-World Therapeutic Pattern in Chinese HER2-Mutant NSCLC the CHAPTER Study

EP.12D.04 Treatment Pattern and Clinical Outcome in Chinese NSCLC Patients with MET Alterationwho Had Disease Progressionon EGFR-TKIs

EP.12D.05 MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations

EP.12D.06 Real-World Cases on Efficacy and Safety of Savolitinib for Elderly Patients with NSCLC Harbouring METex14 Skipping Mutations

EP.12D.07 Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

EP.12E.01 OBX02-011, a Novel Oral ALK and EGFR Dual-target Tyrosine Kinase Inhibitor for the Treatment of Advanced NSCLC Patients

EP.12E.02 Landscape, Management & Outcome of Real-World Fusion-positive Non-Small Cell Lung Cancer (NSCLC)

EP.12E.04 Understanding the Dynamics of TKI Induced Changes in the Tumor Immune Microenvironment for Improved Therapeutic Effect

EP.12E.05 Exploring Clinical Characteristics and Treatment Outcomes of Squamous Cell Lung Cancers Harboring EGFR and ALK Mutations: A Case Series

EP.12F.01 Genome-wide CRISPR-Cas9 Screening Identifies ITGA8 Responsible for Abivertinib Sensitivity in Lung Adenocarcinoma

EP.12F.02 Brigatinib, a Newly Discovered AXL Inhibitor, and Suppresses AXL Mediated Acquired Resistance to Osimertinib in NSCLC

EP.12F.03 Trametinib in the Treatment of Patients with Metastatic Lung Adenocarcinoma Harboring NF1 Mutation

EP.12G.01 PFS as a Surrogate Endpoint for OS in Real-World Patients with ROS1+ advNSCLC in the United States

EP.12G.02 Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada

EP.12H.01 A Phase 2 Study to Assess BDTX-1535, An Oral EGFR Inhibitor, in Patients with Non-Small Cell Lung Cancer

EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas

EP.12H.03 Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in NSCLC Patients with EGFR Mutation

EP.12H.04 Phase II Study of Brigatinib for ALK-Positive Advanced Non-Small Cell Lung Cancer with Brain Metastases: BRAVES Trial (LOGIK2201)

EP.12H.05 Phase II Study on Platinum-Pemetrexed and Lorlatinib Combination in ALK-Positive NSCLC Extracranially Progressing on Lorlatinib

EP.12H.06 A Patient-Centric, Phase II Trial of First-Line Lorlatinib&alk TKIs in China Advanced ALK+ Non-Small Cell Lung Cancer

EP.12H.07 A Phase I Clinical Trial of Carfilzomib in Combination with Sotorasib in Patients with KRASG12C Mutated NSCLC

EP.12H.08 SOHO-02: Phase III Trial of BAY 2927088 In Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations

EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLC

EP.13A.01 Preliminary Efficacy and Safety of Adebrelimab Plus Famitinib as Later-line Treatment for Extensive-Stage Small Cell Lung Cancer: A Phase 2 Trial

EP.13A.02 Adebrelimab Combined with Famitinib and Chemotherapy as First-Line Therapy for ES-SCLC: A Phase II, Single-Arm Exploratory Research

EP.13A.04 A Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC

EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

EP.13B.03 Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

EP.13B.04 The Value of Radiotherapy Based on the Failure of Extensive-Stage Small Cell Lung Cancerin the Era of Immunotherapy

EP.13B.05 Comparison of the Effectiveness of Cisplatin and Carboplatin with Etoposide in Treatment of Small Cell Lung Cancer: Single-center Experience

EP.13B.06 Efficacy and Safety Analysis of Atezolizumab Continuation Beyond Progression in Extensive Small Cell Lung Cancer(ES-SCLC)

EP.13B.08 Enhanced Efficacy of Anlotinib in Small Cell Lung Cancer after Immune Checkpoint Inhibitor Exposure

EP.13B.09 Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive Stage Small Cell Lung Cancer

EP.13B.10 Impact of Pneumonitis from Radiotherapy Combined with Immune Checkpoint Inhibitor Therapy on Tumor Progression and Survival in Patients with Small Cell Lung Cancer

EP.13B.11 Clinical Outcomes of Continuous Immunotherapy Beyond Progression in Patients with Extensive-Stage Small Cell Lung Cancer

EP.13B.12 Chemotherapy Sensitivity for Recurrent Small-Cell Lung Cancer Based on Chemotherapy-Free Interval and Treatment Regimens

EP.13B.13 Radioactive Seed Implantation Combined with PD-L1 Antibody and Chemotherapy Gt in the First-Line Treatment of ES-SCLC: A Retrospective Study.

EP.13B.14 Extensive Small Cell Lung Cancer (SCLC): Maintenance Oral Etoposide Daily for 6 Days Every 3-4 Weeks Until Tumor Progression

EP.13B.15 Radiotherapy Combined with Immunotherapy in the Treatment of Brain Metastases from Small Cell Lung Cancer

EP.13C.01 Prognosis of Surgically Resected Pure and Combined Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy

EP.13C.02 High-Dose Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Real-World Experience from Two Tertiary Centers

EP.13C.03 Investigating Surgery's Role in Stage IIB-IIIB Small Cell Lung Cancer Following Chemo-immunotherapy

EP.13C.04 Is Neoadjuvant Chemoimmunotherapy Better Than Chemotherapy in Patients with Limited-Stage Small Cell Lung Cancer

EP.13C.05 Factors Affecting Outcomes of Limited Stage (IIB-IIIC) Small Cell Lung Cancer: An Analysis of the National Cancer Database.

EP.13C.06 Feasibility of Hippocampal Sparing Radiotherapy in Lung Cancer Patients Requiring Cranial Irradiation (HSWBRT-LC)

EP.13C.07 Long-Term Oncological Outcomes of Resected Bronchopulmonary Neuroendocrine Tumors

EP.13C.08 Leukoencephalopathy and Brain Metastasis in LS-SCLC Patients with and without PCI after Curative Thoracic RT

EP.13D.01 Prognostic Factors and Outcomes of Large Cell Neuroendocrine Carcinoma of Lung: A Single Center Retrospective Cohort Study

EP.13D.02 Low to Intermediate Grade Lung Neuroendocrine Tumours. A Single Centre Real World Experience

EP.13D.03 Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer

EP.13D.04 The Conflicting Impacts of G-CSF on the Therapeutic Efficacy of Chemoimmunotherapy for Extensive Stage Small Cell Lung Cancer

EP.13D.05 Predictive Impact of Peripheral Blood Lymphocyte Subsets and Serum Markers in First-Line Immunotherapy for ES-SCLC——A Real-World Study

EP.13D.06 Factors Affecting Outcomes of Limited-Stage I, IIA (T1-T2, N0, M0) Small Cell Lung Cancer: An Analysis of the National Cancer Database.

EP.13D.07 Impact of Antiemetic Steroid Use on Survival in Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors and Chemotherapy Combination

EP.13D.09 Characteristics and Survival in Never-Smoking Small Cell Lung Cancer Cases an Analysis from the Thoracic Tumor Registry

EP.13D.10 Breast Metastases from Small Cell Lung Carcinoma

EP.13D.12 International Consortium Real-World Outcomes in Extensive Disease Small Cell Lung Cancer Compared to IMPOWER133 And CASPIAN

EP.13D.13 Exploring COVID-19's Impact on Treatment and Survival in Small Cell Lung Cancer

EP.13E.01 Genetic Landscape and Prognostic Markers of Small Cell Lung Cancer: A Comprehensive Study

EP.13E.02 Multi-Omics Analysis of Patients with Extended-Disease Small Cell Lung Cancer Who Received Chemoimmunotherapy: APOLLO-Bio Study.

EP.13E.04 Racial Disparities in Genomic Subtypes of Small Cell Lung Cancer Patients

EP.13E.05 Proteomics Profiling Reveals the Metastasis Mechanism of Small Cell Lung Cancer

EP.14A.01 Prospective Analysis of Patterns of Care and Clinical Outcomes for People Diagnosed with Mesothelioma in Australia

EP.14A.02 Prognostic Factors in Malignant Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: A Baseline Risk Score

EP.14A.03 Analyzing the Impact of COVID-19 Infection on Adverse Outcomes in Mesothelioma: A Multicenter Study

EP.14A.04 Microbial Supernatant Library Screening Suggested that Induction of Ferroptosis is an Effective Therapeutic Strategy Against Mesothelioma

EP.14A.05 Targeting ADAR1 for Mesothelioma Therapy

EP.14A.06 Outcome of Multimodality Therapy Including Radical Surgical Treatment for Malignant Pleural Mesothelioma at a Japanese Regional Institution

EP.14A.07 Molecular Characterization and Validation of Live Cell Biobank for Pleural Mesothelioma

EP.14A.08 Pleural Mesothelioma: Changes the 9th TNM Staging Brought,a Critical Appraisal of the Clinical T-Stage

EP.14A.09 Influence of Post-Pleurectomy/Decortication Peritoneal Dissemination Recurrence of Pleural Mesothelioma on Long-Term Survival

EP.14A.10 The Impact of Serum-Based Inflammatory Biomarkers on Tumor Proliferation and Prognosis in Malignant Pleural Mesothelioma

EP.14A.11 Mortality Based on Treatment in Stage III Non-Epithelioid Pleural and Pericardial Mesothelioma - A Review from a National Cohort

EP.14A.12 Impact of a Multidisciplinary Team on Overall Survival in Patients with Pleural Mesothelioma: Experience from a Single Institution in Mexico

EP.14A.13 Gender and Racial Disparities in Hospitalization and Outcomes of Malignant Mesothelioma in the United States

EP.14A.14 Clinical Insights and Survival Outcomes of Malignant Pleural Mesothelioma: An Experience from a Tertiary Care Centre in India

EP.14A.15 Racial Disparities in Risk of Bone Metastasis at Diagnosis of Malignant Pleural Mesothelioma

EP.14A.17 A Retrospective Study Looking at the Demographics and Occupations of Patients with Mesothelioma in Kent, South East England

EP.14A.18 Single-Center Experience of Hyperthermic Intrathoracic Chemoperfusion for Malignant Mesothelioma

EP.14A.19 Pleurectomy Decortication for Malignant Pleural Mesothelioma: Safe and Faster Technique

EP.14A.20 Hyperthermic Intrathoracic Chemotherapy Following Cytoreductive Surgery in Patients with Pleural Mesothelioma

EP.14B.01 Prognostic Impact of Tumour Size in Resected Thymic Epithelial Tumours - A Validation Analysis of the 9th TNM Staging System -

EP.14B.03 Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Absolute Lymphocyte Count (ALC) In Thymic Epithelial Tumors

EP.14B.05 What Do We Know About Thymic Epithelial Tumors? Demographic and Survival Analysis from a Single Academic Center in Argentina

EP.14B.06 A Retrospective Multicenter Study Evaluating Experience of Perioperative Treatment for Thymic Squamous Cell Carcinoma

EP.14B.07 Does Surgical Incision Affect Quality of Life in Masaoka Stage 1-2 Thymomas?

EP.14C.01 Coexisting Pulmonary Tuberculosis and Primary Lung Cancer: Prevalence of Diagnostic, Treatment and Outcome

EP.14C.03 Long-Term Outcomes of Unresectable Tracheobronchial Tumors Treated with Radiotherapy- Analysis from a Tertiary Cancer Centre

EP.14C.04 Micro Neck Incision Combined with VATS for Resection of Superior Mediastinal Neoplasms

EP.14C.05 The Management of Solitary Fibrous Tumors of Chest in a Center

EP.14C.06 Surgical and Local Treatment of Pain in Tietze Syndrome: Our Experience in University Hospital “Shefqet Ndroqi” Tirana Albania

EP.14C.07 Hyperossosis of the Right 10th Rib the Osteochondral Part that Compresses the Dexter Lobe of the Liver

EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma - Case Report

EP.14D.01 Cadonilimab Plus Bevacizumab and Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma: A Single-Arm Phase II Study

EP.15A.01 Lung Cancer Patients in a Nationwide Oncology Navigation Program

EP.15A.02 Prospective Evaluation of A Single-Day Multidisciplinary Clinic for Patients with Locally Advanced Non-Small Cell Lung Cancer

EP.15A.03 Lung Cancer Multidisciplinary Teams in China Show Multi-faceted Similarities and Differences Compared to Europe and Canada

EP.15B.02 Real-World Data from Advanced Practice Nurse Care in Lung Cancer in a Private Clinic in Brazil.

EP.15B.03 Pilot Web-Based Study of Functional Status and Quality of Life Benefits Associated with Darbepoetin Alfa Use in Anemic Patients with Lung Cancer

EP.15B.04 High-Fiber Intake Predicts Overall Survival in Lung Cancer Patients - Real-World Analyses

EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study

EP.16A.01 Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey

EP.16B.01 UK and US Patient Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitors Treatments

EP.16B.02 Lung Cancer Patients' Preferred Methods of Receiving Information from their Treatment Teams: Insights from a Global Patient Experience Survey

EP.16C.01 The INSPIRE (INformation Support through Patient Involvement for Research and Education) Project

EP.16E.01 Advancing Patient Empowerment: The Growth and Impact of Educational Lung Cancer Patient Groups

EP.16E.02 15 Years of the Lung Cancer Living Room Expert Speaker Series Provides Critical Education to Global Audience

EP.16F.01 Priorities and Support Needs for People Impacted by Lung Cancer in Ireland

EP.16F.02 Availability of Supportive Care in Lung Cancer: A Global Perspective

EP.16F.03 Lung Cancer Patients' Preferred Methods of Involvement with their Treatment Teams: Insights from a Global Patient Experience Survey

EP.16G.01 Ready, Set, Screen: Evaluating Community Readiness for Lung Cancer Screening Among Non-Hispanic Black Populations in Florida

EP.17A.01 The Cumulative Incidence of Brain Metastases in US Medicare Patients with ALK+ mNSCLC Treated with Second-generation ALK TKIs

EP.17A.02 Diagnostic and Treatment Gaps in NSCLC Management Compared to NCCN Recommendations: An Audit Analysis of 214 Cases.

EP.17A.03 NOVA: A Conversational Generative Agent for Thoracic Oncology Decision-Making

EP.17A.04 Real-World Rates of Infusion-Related Reactions in Patients with EGFR-Mutant NSCLC Receiving Amivantamab

EP.17A.05 Efficient Lung Cancer Multidisciplinary Team (MDT) Management Strategy for the Hospitals with High-Volume Patients

EP.17A.06 Real-World Trends in Screening and Evaluation of Paraneoplastic Syndromes among Patients with Small Cell Lung Cancer

EP.17A.07 ROSETTA-LUNG: MultidisciplinaRy Oncology StratEgies for Team-Based Treatment ConcordAnce in Lung Cancer Diagnosis and Treatment Decisions

EP.17A.08 Development of the First Lung Cancer Clinical Pathway in Chinese Counties

EP.17B.01 Timelines of Lung Cancer Pathway in Rural and Regional NSW; A Retrospective Study in Hunter New England LHD

EP.17B.02 Racial Disparities in Patients with Lung Cancer Requiring Intubation: A National Inpatient Study

EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC)

EP.17B.04 Racial/Ethnic Differences in Risk of Mortality of Men and Women with Lung Cancer

EP.17B.05 Impact of Race and Ethnicity on Financial Toxicity and Outcomes in Lung Cancer

EP.17B.06 Survival by Ethnicity and Socioeconomic Status in Patients Diagnosed with Lung Cancer: A 11-year Single Centre Experience

EP.17C.01 Increasing the Earlier Detection of Lung Cancer: A Toolbox for Change

EP.17C.02 Nodule-AFM: Construction and Application of LLM and Multi-Agent Collaborative Based Active Follow-Up Management for Pulmonary Nodule Patients

EP.17D.01 Trends in Lung Cancer Incidence Among Individuals Under 50: A Retrospective Analysis of the National Inpatient Sample (NIS) Database

EP.17E.01 Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC

EP.17E.02 Assessing the True Cost of Lung Cancer Screening - Chargemaster, Payer, And Cash Price Discrepancies for CT Chest Imaging

EP.17E.03 Using Healthcare Claims to Predict Costs by Stage for Medicare and Commercially Insured Patients with Non-Small Cell Lung Cancer

EP.17F.01 Care Pathways for Lung Cancer: Building a Foundation for Optimal Care

EP.17F.02 Three-Stage Evolution of Lung Cancer Multidisciplinary Team in China

EP.17F.03 An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway

EP.17F.04 Challenges and Opportunities in Multidisciplinary Team (MDT) Consultations for Advanced-Stage Lung Cancer Patients in China

EP.17F.05 The Impact of COVID-19 On Time Toxicity in Advanced Lung Cancer Patients

EP.17F.06 Enhancing Lung Cancer Care and Patient Access at Regional Level - The Impact of Inter-Hospital Remote Multidisciplinary Team Consultations

EP09A.08 Assessment of MR-Guided Single-Fraction SABR/SBRT of Peripheral Lung Tumors: Dosimetric and Clinical Outcomes - A Prospective Study